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Preston et al. reported an interesting clinical study of
patients with acute and chronic pulmonary hypertension in
which the addition of inhaled nitric oxide (iNO) potentiated
the pulmonary vasodilator effects of sildenafil.1 Accordingly,
recent studies have suggested that direct or indirect
activation of the NO-cyclic guanosine 3050-monophosphate
(NO-cGMP) pathway in the pulmonary vessels may attenuate
pulmonary hypertension from many etiologies. Indeed, we
would like to add information from recent studies addressing
the possible potentiation of the pulmonary vasodilatory
effects produced by sildenafil. We have recently shown that
L-arginine did not enhance the pulmonary vasodilator effects
produced by sildenafil after pulmonary hypertension in-
duced by acute pulmonary embolism (PH-APE),2 although L-
arginine significantly attenuated PH-APE when it was added
to the lung perfusate before lung embolization.3 We believe
that increased reactive oxygen species induced by APE may
lead to endothelial NO synthase (eNOS) uncoupling2,4 and it
is possible that stimulation of dysfunctional eNOS with L-
arginine administered after APE increases superoxide
production instead of increasing NO formation, thus pre-
cluding L-arginine from producing beneficial effects. Finally,
we would like to comment on another study showing that a
NO-releasing drug (DETA-nonoate) did not enhance the
pulmonary vasodilator effects of sildenafil during PH-APE.5
Together, these recent studies suggest that NO-donors or the
substrate for NO synthesis do not enhance the pulmonary
vasodilatory effects produced by sildenafil during PH-APE
without producing systemic effects. It is possible, however,
that alternative approaches such as the administration ofnt matter & 2007 Elsevier Ltd. All rights reserved.
2006.10.028high doses of inhaled NO, inhaled NO donors or inhaled
guanylate cyclase activators may well be able to increase
the effects produced by sildenafil, as reported by Preston
et al.1
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